Shares of La Jolla Pharmaceutical (NASDAQ:LJPC) have received an average recommendation of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $63.33.
A number of analysts recently commented on the company. Jefferies Group reiterated a “buy” rating and set a $40.00 price objective on shares of La Jolla Pharmaceutical in a research report on Tuesday, October 3rd. Cowen reiterated a “buy” rating and set a $55.00 price objective on shares of La Jolla Pharmaceutical in a research report on Friday, December 22nd. BidaskClub upgraded La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. ValuEngine upgraded La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 26th. Finally, JPMorgan Chase & Co. cut La Jolla Pharmaceutical from an “overweight” rating to an “underweight” rating and set a $20.00 price objective for the company. in a research report on Friday, December 8th.
Shares of La Jolla Pharmaceutical (NASDAQ:LJPC) traded down $2.34 during trading hours on Friday, hitting $30.08. The stock had a trading volume of 376,831 shares, compared to its average volume of 612,216. The company has a market capitalization of $666.13, a P/E ratio of -5.90 and a beta of 1.63. La Jolla Pharmaceutical has a 1 year low of $16.71 and a 1 year high of $39.28.
In related news, COO Jennifer Carver purchased 1,000 shares of La Jolla Pharmaceutical stock in a transaction on Thursday, December 27th. The stock was acquired at an average price of $33.22 per share, for a total transaction of $33,220.00. Following the completion of the transaction, the chief operating officer now directly owns 4,500 shares in the company, valued at approximately $149,490. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Laura L. Douglass sold 10,000 shares of the company’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $32.32, for a total value of $323,200.00. The disclosure for this sale can be found here. 25.47% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Emory University purchased a new stake in La Jolla Pharmaceutical in the second quarter worth about $1,410,000. Cowen Inc. boosted its stake in shares of La Jolla Pharmaceutical by 375.6% in the third quarter. Cowen Inc. now owns 93,700 shares of the biopharmaceutical company’s stock worth $3,259,000 after acquiring an additional 74,000 shares during the period. Candriam Luxembourg S.C.A. bought a new position in shares of La Jolla Pharmaceutical in the third quarter worth about $6,295,000. Vanguard Group Inc. boosted its stake in shares of La Jolla Pharmaceutical by 23.3% in the second quarter. Vanguard Group Inc. now owns 816,779 shares of the biopharmaceutical company’s stock worth $24,316,000 after acquiring an additional 154,494 shares during the period. Finally, Pictet Asset Management Ltd. bought a new position in shares of La Jolla Pharmaceutical in the third quarter worth about $13,266,000.
TRADEMARK VIOLATION WARNING: “La Jolla Pharmaceutical (LJPC) Receives Average Recommendation of “Buy” from Brokerages” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://weekherald.com/2018/01/20/la-jolla-pharmaceutical-ljpc-receives-average-recommendation-of-buy-from-brokerages.html.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.